p-SCN-Bn-DOTA

p-SCN-Bn-DOTA is a bifunctional chelating agent. p-SCN-Bn-DOTA can simultaneously chelate radionuclides and link monoclonal antibody for radioimmunotherapy of tumor.

Product information

CAS Number: 127985-74-4

Molecular Weight: 551.61

Formula: C24H33N5O8S

Chemical Name: 2-[4, 7, 10-tris(carboxymethyl)-6-[(4-isothiocyanatophenyl)methyl]-1, 4, 7, 10-tetrazacyclododec-1-yl]acetic acid

Smiles: OC(=O)CN1CCN(CC(O)=O)CCN(CC(O)=O)C(CC2C=CC(=CC=2)N=C=S)CN(CC(O)=O)CC1

InChiKey: UDOPJKHABYSVIX-UHFFFAOYSA-N

InChi: InChI=1S/C24H33N5O8S/c30-21(31)13-26-5-6-27(14-22(32)33)9-10-29(16-24(36)37)20(12-28(8-7-26)15-23(34)35)11-18-1-3-19(4-2-18)25-17-38/h1-4,20H,5-16H2,(H,30,31)(H,32,33)(H,34,35)(H,36,37)

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: To be determined

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

p-SCN-Bn-DOTA is complexed with 5 different metal ions: In(III), Y(III), Lu(III), Gd(III) and Cu(II).

References:

1. Giannini G, et, al. Synthesis and preliminary in vitro evaluation of DOTA-Tenatumomab conjugates for theranostic applications in tenascin expressing tumors. Bioorg Med Chem. 2019 Aug 1;27(15):3248-3253.
2. Vera DRB, et, al. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors. Cancer Biother Radiopharm. 2011 Jun;26(3):287-97.

Products are for research use only. Not for human use.